American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

David Neskey – Charleston South Carolina

This AHNS online physician locator helps you find a match for your medical needs.

Members: How to Modify your profile 

Instructions on using the search:

  • The easiest way to search is to drag and zoom the map below until you are seeing your desired geographical area.  Once there, click on the pins to see member information
  • You may use the geosearch box to autocomplete an area and search that way
  • If you wish to search by other criteria, use the text search box

← Go back

David Neskey

Medical University of South Carolina

135 Rutledge Avenue
MSC 550
Charleston, South Carolina 29403
United States
Map It

Email hidden; Javascript is required.

David M. Neskey, M.D., MSCR, FACS is an assistant professor in the Department of Otolaryngology in the division of Head and Neck Surgical Oncology.  Originally from Massachusetts he received his medical degree from Albany Medical College with a distinction in research in 2006 followed by a residency in Otolaryngology Head and Neck Surgery at the University of Miami.  He then completed a fellowship in head and neck surgical oncology at MD Anderson Cancer Center in Houston.  This training experience was comprised of two years dedicated to basic science research followed by a year committed to the management of patients with head and neck cancer.

Dr Neskey’s clinical focus is on the care of patients with benign and malignant neoplasias of the head and neck including oral cavity, oropharyngeal, laryngeal lesions, and skullbase,  advanced melanoma and nonmelanoma skin cancers, and lesions of the salivary glands, thyroid and parathyroids.  His specific interests are squamous cell carcinoma of the oral cavity and oropharynx along with advanced skin cancer and skull base tumors.  He currently sees patients in Hollings Cancer Center.

Dr Neskey has published over 30 peer reviewed articles and book chapters  focused on the molecular pathways and genomic alterations associated with head and neck squamous cell carcinoma.  Based on this work he is currently funded through the National Institute of Health to study the mechanisms of invasion and metastases in head and neck cancer.  In addition to his lab based studies, Dr. Neskey is the principle investigator in several ongoing trials, including an investigator initiated trial investigating immunotherapy a presurgical treatment for patients with oral cavity cancer. He is board certified by the American Board of Otolaryngology and is a member of the American Head and Neck Society, American Academy of Clinical Research, and a Fellow of the American College of Surgeons.

Investigator Initiated Phase II Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer (NCT03021993).

Role: Sponsor and PI

  1. Fabie JE, Hatch JL, Cross AW, Oyer AW, Neskey DM, McRackan TR. Metastatic Salivary Ductal Carcinoma to the Mastoid Segment of the Facial Nerve. Otol Neurotol. 2018 Jul 30. doi: 10.1097/MAO.0000000000001923. [Epub ahead of print] PMID:30063500
  2. Janz TA, Neskey DM, Nguyen SA, Lentsch EJ. Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas? Am J Otolaryngol. 2018 Jun 8. pii: S0196-0709(18)30415-0. doi: 10.1016/j.amjoto.2018.06.007. [Epub ahead of print] Review.
  3. Grauzam S, Brock AM, Holmes CO, Tiedeken JA, Boniface SG, Pierson BN, Patterson DG, Coaxum SD, Neskey DM, Rosenzweig SA. NEDD9 stimulated MMP9 secretion is required for invadopodia formation in oral squamous cell carcinoma. Oncotarget. 2018 May 22;9(39):25503-25516. doi: 10.18632/oncotarget.25347. eCollection 2018 May 22.
  4. Zhan KY, Morgan PF, Neskey DM, Kim JJ, Huang AT, Garrett-Mayer E, Day TA. Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases. Head Neck. 2018 May 14. doi: 10.1002/hed.25178. [Epub ahead of print]
  5. Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, Sharma AK, Morgan PF, Nguyen SA, Day TA.  Primary Surgery vs Radiotherapy for Early Stage Oral Cavity Cancer. Otolaryngol Head Neck Surg. 2017 Dec 1:194599817746909. doi: 10.1177/0194599817746909. PMID: 29256326
  6. Borucki RB, Neskey DM, Lentsch EJ. Malignant Fibrous Histiocytoma: Database Review Suggests a Favorable Prognosis in the Head and Neck. Laryngoscope. 2017 Oct 8. doi10.1002/lary.26909. PMID: 28988458
  7. Ellis MA, Graboyes EM, Day TA, Neskey DM. Prognostic Factors and Occult Nodal Disease in Carcinoma of the Oral Cavity and Oropharynx: An Analysis of the National Mucoepidermoid Cancer Database.  Oral Oncol. 2017 Sep; 72:174-178. doi:10.1016/j.oraloncology.2017.07.025. Epub 2017 Jul 27.  PMID: 28797455
  8. Coaxum SD, Tiedeken J, Garrett-Mayer E, Myers JN, Rosenzweig SA, Neskey DM. The Tumor Suppressor Capability of p53 is Dependent on Non-Muscle Myosin IIA in Head and Neck Cancer. Oncotarget. 2017 Jan. doi:10.18632/oncotarget.14967. PMID: 28160562
  9. Ellis MA, Gerry DR, Neskey DM, Lentsch EJ.  Ewing Sarcoma of the Head and Neck. Ann Otol Rhinol Laryngol. 2017 Mar; 126(3):179-184. doi: 10.1177/0003489416681322. PMID: 28056517
  10. Majumder M, House R, Palanisamy N, Qie S, Day TA, Neskey DM, Diehl JA, Palanisamy V. RNA-Binding Protein FXR1 Regulates p21 and TERC RNA to Bypass p53-Mediated Cellular Senescence in OSCC. PLoS Genet. 2016 Sep 8; 12(9):e1006306. doi: 10.1371/journal.pgen.1006306. PMID: 27606879
  11. *Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, Hicks SC, McDonald TO, Ow TJ, Ortega Alves M, Pickering CR, Skinner HD, Zhao M, Sturgis EM, Kies MS, El-Naggar A, Perrone F, Licitra L, Bossi P, Kimmel M, Frederick MJ, Lichtarge O, Myers JN.  Evolutionary Action Score of TP53 Coding Variants (EAp53) is Predictive of Platinum Response in Head and Neck Cancer Patients.  Cancer Res. 2015 Feb 17. pii: canres.2729.2014. * Denotes shared first author
  12. Neskey DM, Osman AO, Ow TJ, Dr., Katsonis P , McDonald T, Hicks SC, Hsu TK, Pickering CR, Ms. Ward A, Patel A, Yordy JS, Skinner HD, Giri U, Sano D, Story MD, Beadle BM, El-Naggar AK, Kies MS, William WN, Caulin C, Frederick M, Kimmel M, Myers, JN, Lichtarge O.  Evolutionary Action Score of TP53 (EAp53) Identifies High Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Research 2015 Jan 29. pii: canres.2735.2014.
  13. Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.  Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence.  Mol Cancer Ther. 2014 Dec 10. pii: molcanther.0735.2014.
  14. Pickering CR, Zhang J, Neskey DM, Zhao M, Jasser SA, Wang J, Ward A, Tsai CJ, Ortega Alves MV, Zhou JH, Drummond JA, El-Naggar AK, Gibbs RA, Weinstein JN, Wheeler DA, Wang J, Frederick MJ, Myers JN.  Squamous Cell Carcinoma of the Oral Tongue in Young Non-smokers is Genomically Similar to Tumors in Older Smokers.  Clin Cancer Res. 2014 May 29. pii: clincanres.0565.2014. [Epub ahead of print].
  15. Neskey DM, Klein JD, Hicks S, Garden AS, Bell D, El-Naggar AK, Kies MS, Weber RS, Kupferman ME.  Prognostic Factors Associated Decreased Survival in Acinic Cell Carcinoma.  JAMA Otolaryngol Head Neck Surg. 2013 Sep 26. doi: 10.1001/jamaoto.2013.4728
  16. Gadhikar MA, Sciuto MR, Ortega Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ.  Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.  Mol Cancer Ther. Mol Cancer Ther. 2013 Sep;12(9):1860-73.
  17. Yang CZ, Ma J, Luo QQ, Neskey DM, Zhu DW, Liu Y, Myers JN, Zhang CP, Zhang ZY, Zhong LP.  Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.  J Oral Pathol Med. 2013 May 26. doi: 10.1111/jop.12091. [Epub ahead of print].
  18. Pickering CR, Zhang J Suk, Yoo SY, Neskey DM, Xie TX, El-Naggar AK, Weinstein JN, Wang J, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ.  Integrated genomic characterization of oral cavity squamous cell carcinoma identifies frequent genomic drivers.  Cancer Discovery.  2013 Apr 25. [Epub ahead of print].
  19. Perez A, Neskey DM, Wen J, Pereira L, Reategui EP, Goodwin WJ, Carraway KL, Franzmann EJ.  CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression.  Oral Oncol. 2013 Apr;49(4):306-13.  Epub 2012 Dec 20.
  20. Eloy JA, Neskey DM, Vivero RJ, Ruiz JW, Choudhry OJ, Casiano RR.  High-resolution computed tomography analysis of the frontal sinus ostium: A pilot study.  Am J Otolaryngol. 2013 Mar; 34(2):99-102. Epub 2012 Oct 23.
  21. Ma J, Liu Y, Huang XL, Zhang ZY, Myers JN, Neskey DM, Zhong LP.  Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: A meta-analysis.  Oral Oncol. 2012 Jul 14. Epub ahead of print
  22. Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli S, Weed D, Sargi Z.  Outcomes after surgical resection of head and neck paragangliomas: A review of 61 patients.  Skull Base.  21:171-76, 2011
  23. Neskey DM, Eloy JA, Casiano RR.  Nasal, septal, and turbinate anatomy and embryology.  Otolaryngology Clinics of North America.  42;193-205, 2009.
  24. Lee SL, Neskey DM, Mouzakes J.  Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review.  Ear Nose Throat J.  88(8):12-4, 2009.
  25. Neskey DM, Ambesi AA, Pumiglia KM, McKeown-Longo PJ.  Endostatin and anastellin inhibit distinct aspects of the angiogenic process.  J Exp Clin Cancer Res. 27:61-68, 2008 November.
  26. Gross KL, Neskey DM, Manchanda N, Weremowicz S, Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K, Bullerdiek J, Morton CC.  HMGA2 expression in uterine leiomyomata and myometrium: quantitative analysis and tissue culture studies.  Genes, Chromosomes, & Cancer.  38(1):68-79, 2003 September.
  27. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC.  Fusion transcripts involving HMGA2 are not a common molecular mechanism on uterine leiomyomata with rearrangements in 12q15.  Cancer Research.  63(6):1351-8, 2003 March.
  28. Dal Cin P, Quade BJ, Neskey DM, Kleinman MS, Weremowicz S, Morton CC.  Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24).  Genes, Chromosomes, & Cancer.  36(2):05-6, 2003 February.
  29. Quade BJ, Dal Cin P, Neskey DM, Weremowicz S, Morton CC.  Intravenous Leiomyomatosis: molecular and cytogenetic analysis of a case.  Modern Pathology.  15(3):351-6, 2002 March.
  30. Nucci MR, Weremocicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ.  Chromosomal Translocation t(8;12) Induces Aberrant HMGIC Expression in Aggressive Angiomyxomas of the Vulva.  Genes, Chromosomes, and Cancer.  32(2):172 -176, 2001 October.